AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

3.440

+0.010 (0.29%)

At close: Apr 9, 2026, 4:00 PM EDT

3.480

+0.040 (1.16%)

After-hours: Apr 9, 2026, 7:47 PM EDT

AbCellera Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	75.13	28.83	38.03	485.42	375.2
Revenue Growth (YoY)	160.56%	-24.17%	-92.17%	29.38%	60.92%
Cost of Revenue	186.83	167.26	175.66	174.32	107.58
Gross Profit	-111.7	-138.43	-137.63	311.11	267.63
Selling, General & Admin	83.23	85.49	75.18	66.76	48.76
Operating Expenses	105.4	144.34	99.57	86.2	63.21
Operating Income	-217.1	-282.77	-237.21	224.91	204.41
Interest & Investment Income	28.33	38.47	42.25	16.08	3.33
Other Non Operating Income (Expenses)	10.18	11.2	17.03	8.21	11.91
EBT Excluding Unusual Items	-178.6	-233.1	-177.93	249.2	219.65
Gain (Loss) on Sale of Investments	1	17.4	3.9	-1.7	-0.5
Asset Writedown	-	-32	-	-8.4	-
Other Unusual Items	-	47.3	-	-	-
Pretax Income	-177.6	-200.4	-174.03	239.1	219.15
Income Tax Expense	-31.18	-37.54	-27.63	80.58	65.69
Net Income	-146.41	-162.86	-146.4	158.52	153.46
Net Income to Common	-146.41	-162.86	-146.4	158.52	153.46
Net Income Growth	-	-	-	3.29%	29.05%
Shares Outstanding (Basic)	299	294	289	285	276
Shares Outstanding (Diluted)	299	294	289	315	318
Shares Change (YoY)	1.49%	1.79%	-8.15%	-1.09%	20.96%
EPS (Basic)	-0.49	-0.55	-0.51	0.56	0.56
EPS (Diluted)	-0.49	-0.55	-0.51	0.50	0.48
EPS Growth	-	-	-	4.17%	6.21%
Free Cash Flow	-174.07	-186.95	-120.82	206.7	186.13
Free Cash Flow Per Share	-0.58	-0.64	-0.42	0.66	0.58
Gross Margin	-148.68%	-	-	64.09%	71.33%
Operating Margin	-288.98%	-980.70%	-623.82%	46.33%	54.48%
Profit Margin	-194.88%	-564.83%	-385.00%	32.66%	40.90%
Free Cash Flow Margin	-231.69%	-648.40%	-317.75%	42.58%	49.61%
EBITDA	-194.93	-223.92	-212.81	244.35	218.88
EBITDA Margin	-259.47%	-	-	50.34%	58.34%
D&A For EBITDA	22.17	58.85	24.4	19.44	14.47
EBIT	-217.1	-282.77	-237.21	224.91	204.41
EBIT Margin	-288.98%	-	-	46.33%	54.48%
Effective Tax Rate	-	-	-	33.70%	29.97%
Revenue as Reported	75.13	28.83	38.03	485.42	375.2

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q